Energy Fuels Announces 2019 Results

LAKEWOOD, CO, March 16, 2020 /CNW/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”) today reported its financial results for the year ended December 31, 2019. The Company’s annual report on Form 10-K has been filed with the U.S. Securities and Exchange Commission (“SEC“) and may be viewed on the Electronic Document Gathering…

CURE Pharmaceutical Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction

GlobeNewswire•March 17, 2020 ED Drug Market Expected to Reach US$6.5B by 2025 OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using…

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

GlobeNewswire•February 12, 2020 Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES, Feb. 12, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction…

Energy Fuels Applauds President Trump’s 10-Year, $1.5 Billion Plan to Establish U.S. Uranium Reserve

PR Newswire•February 11, 2020 LAKEWOOD, CO, Feb. 11, 2020 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), a leading uranium producer in the U.S., applauds President Trump for yesterday announcing a budget that seeks $150 million per year over the next 10 years (totaling $1.5 billion over that…

CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

GlobeNewswire•February 5, 2020 CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines OXNARD, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of…

It’s CURE Pharmaceutical’s 2019 Year in Review

Greetings, As we bid farewell to 2019, we proudly reflect on a year replete with milestones and forward strides for CURE. 2019 marked a significant level of progress that stemmed from our strong patent positioning and pipeline advancement. In 2019, we attracted a deep bench of scientific and industry talent to our staff and board…

CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors

Industry veteran brings 40 year of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience…

CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

GlobeNewswire•November 14, 2019 OXNARD, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents…